Celgene CC-4047-MM-007 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer - Hematology/ Blood
Principal Investigator: Philip Kuriakose, MD
The purpose of this study is compare the efficacy of the combination of Pomalidomide, Bortezomib and Dexamethasone to the combination of Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of Pomalidomide, Bortezomib and Dexamethasone is compared to the combination of Bortezomib and Dexamethasone.
18 years or older with a diagnosis of Multiple Myeloma; at least 1 but no greater than 3 prior anti-myeloma treatment regimens; disease progression during or after the last anti-myeloma therapy; must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles.